Sage seeks $575M in pub­lic of­fer­ing; Pfiz­er inks dis­cov­ery pact with Chi­nese firm

→ Sage Ther­a­peu­tics is hop­ing to raise a whop­ping $575 mil­lion through its lat­est pub­lic of­fer­ing, an­nounced a day af­ter the biotech $SAGE re­ceived a break­through ther­a­py des­ig­na­tion for its lead drug on ma­jor de­pres­sive dis­or­der. In an SEC fil­ing, the com­pa­ny wrote it “an­tic­i­pates that the net pro­ceeds of the of­fer­ing, to­geth­er with its ex­ist­ing cap­i­tal re­sources and es­ti­mat­ed brex­anolone IV prod­uct sales, if the prod­uct is ap­proved, will en­able the com­pa­ny to fund its op­er­at­ing ex­pens­es and cap­i­tal ex­pen­di­ture re­quire­ments in­to 2020.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER